GlaxoSmithKline Plc, Europe’s largest drugmaker, has signed an agreement with France’s Institut Pasteur to develop a SARS vaccine. Scientists from the two organizations aim to produce a sub-unit vaccine, derived from viral proteins. Such a vaccine would protect individuals from the risk of infection, since viral proteins themselves are not infectious. GSK vaccine head Jean Read more about Glaxo And Institut Pasteur Work On Sars Vaccine[…]